CTOs on the Move

La Jolla Pharmaceutical

www.lajollapharmaceutical.com

 
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is La Jolla`s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is La Jolla`s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is our next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of ...
  • Number of Employees: 250-1000
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details

Similar Companies

Alimera Sciences

Alimera Sciences, Inc., headquartered in Alpharetta, Georgia, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera`s European operations are conducted from London by its subsidiary, Alimera Sciences Limited.

Dey Pharmaceuticals

Dey Pharmaceuticals is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

ABIGO MEDICAL AB

ABIGO MEDICAL AB is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nuvo Research

Nuvo Research Inc. is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oncology Pharma

Oncology Pharma, Inc. is a pioneering oncology company dedicated to licensing, developing, manufacturing and commercializing therapeutics. The company has assembled a team of executives and advisors with proven multi-disciplinary expertise in the field of oncology, therapeutics and leadership to identify, negotiate and amalgamate “best in class” research, technologies, therapeutics and delivery mechanisms that are synergistic and collaborative. The goal is to create value, reduce costs and increase the speed of regulatory approval and commercialization of effective and safer cancer drugs.